TriangleItraconazole (NCT05563766)
Itraconazole trial for Esophageal Adenocarcinoma (NCT05563766). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with resectable esophageal or gastroesophageal-junction cancer scheduled for chemoradiation or perioperative chemoimmunotherapy and surgery. Distant metastases exclude entry.
The idea: test itraconazole, an antifungal drug that inhibits growth and blood-vessel signaling pathways, around standard treatment. Patients take 300 milligrams orally twice daily for two weeks beforehand, then six to eight weeks after chemoradiation, or four to six after chemoimmunotherapy, before surgery. Surgical tissue shows whether cancer remains; researchers monitor drug levels and toxicity.
This phase 2 study plans 78 patients. David Wang leads seven recruiting US VA sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.